{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:40:22Z","timestamp":1756284022140,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,3,10]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Chronic thromboembolic pulmonary hypertension (CTEPH) involves non-resolving thromboemboli in the pulmonary arteries. Treatment for CTEPH includes lifelong anticoagulation and determination of patients who have disease which is operable versus inoperable. Pulmonary arterial hypertension (PAH) targeted therapies are oftentimes used as a bridge to pulmonary thromboendarterectomy (PTE), though riociguat is the only Food and Drug Administration (FDA)-approved therapy for CTEPH. There is a paucity of data regarding the efficacy of other PAH therapies, particularly as a bridge to PTE. Here, we present a case report of severe CTEPH related to ventriculoatrial shunt in which intravenous treprostinil was used as a bridge to PTE.<\/jats:p>","DOI":"10.1136\/bcr-2020-235806","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:38:57Z","timestamp":1659109137000},"page":"e235806","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Successful use of intravenous treprostinil as a bridge to pulmonary thromboendarterectomy"],"prefix":"10.1136","volume":"14","author":[{"given":"Ashley","family":"Cattran","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-1707","authenticated-orcid":false,"given":"Jean","family":"Elwing","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"2025082701055103000_14.3.e235806.1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccm.2018.04.018","article-title":"Chronic thromboembolic pulmonary hypertension: an update","volume":"39","author":"Elwing","year":"2018","journal-title":"Clin Chest Med"},{"key":"2025082701055103000_14.3.e235806.2","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00009111"},{"key":"2025082701055103000_14.3.e235806.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00087608"},{"key":"2025082701055103000_14.3.e235806.4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1160\/TH04-10-0657","article-title":"Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension","volume":"93","author":"Bonderman","year":"2005","journal-title":"Thromb Haemost"},{"key":"2025082701055103000_14.3.e235806.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209657"},{"key":"2025082701055103000_14.3.e235806.6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S2213-2600(16)30022-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial","volume":"4","author":"Simonneau","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025082701055103000_14.3.e235806.7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10741-019-09798-x","article-title":"Advances in targeted therapy for chronic thromboembolic pulmonary hypertension","volume":"24","author":"Zhang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"2025082701055103000_14.3.e235806.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2681"},{"key":"2025082701055103000_14.3.e235806.9","first-page":"CD012621","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","volume":"1","author":"Barnes","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082701055103000_14.3.e235806.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.08.059"},{"key":"2025082701055103000_14.3.e235806.11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-2600(17)30305-3","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study","volume":"5","author":"Ghofrani","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025082701055103000_14.3.e235806.12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S2213-2600(18)30367-9","article-title":"Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial","volume":"7","author":"Sadushi-Kolici","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025082701055103000_14.3.e235806.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2006.12.014"},{"key":"2025082701055103000_14.3.e235806.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02394.x"},{"key":"2025082701055103000_14.3.e235806.15","first-page":"618","article-title":"Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions","volume":"5","author":"Scelsi","year":"2004","journal-title":"Ital Heart J"},{"key":"2025082701055103000_14.3.e235806.16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijcard.2010.10.115","article-title":"ACTH deficiency and PGI(2) therapy in chronic thromboembolic pulmonary hypertension","volume":"146","author":"Ikari","year":"2011","journal-title":"Int J Cardiol"},{"key":"2025082701055103000_14.3.e235806.17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000107977","article-title":"Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension","volume":"76","author":"Krug","year":"2008","journal-title":"Respiration"},{"key":"2025082701055103000_14.3.e235806.18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.3.841"},{"key":"2025082701055103000_14.3.e235806.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.05.019"},{"key":"2025082701055103000_14.3.e235806.20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.6.1636"},{"key":"2025082701055103000_14.3.e235806.21","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.5.1583"},{"key":"2025082701055103000_14.3.e235806.22","doi-asserted-by":"publisher","DOI":"10.1136\/heart.87.4.340"},{"key":"2025082701055103000_14.3.e235806.23","doi-asserted-by":"publisher","DOI":"10.1159\/000092920"},{"key":"2025082701055103000_14.3.e235806.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198198","article-title":"Factors predicting outcome after pulmonary endarterectomy","volume":"13","author":"Tromeur","year":"2018","journal-title":"PLoS One"},{"key":"2025082701055103000_14.3.e235806.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.05.014"},{"key":"2025082701055103000_14.3.e235806.26","doi-asserted-by":"publisher","DOI":"10.1086\/529552"},{"key":"2025082701055103000_14.3.e235806.27","first-page":"170","article-title":"Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025082701055103000_14.3.e235806.28","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0245"},{"key":"2025082701055103000_14.3.e235806.29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10096-013-1822-z","article-title":"Central venous catheter-related blood stream infections in patients receiving intravenous iloprost for pulmonary hypertension","volume":"32","author":"Sammut","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-235806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:05:59Z","timestamp":1756281959000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-235806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,25]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/bcr-2020-235806"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-235806","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}